ClinicalTrials.gg
Active, not recruitingNCT05831176ENGAGEUpdated Jul 1, 2026

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

A Phase 2 interventional study of Dupilumab in Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD) and Eosinophilic Gastrointestinal Disease (EGID), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 53 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Eosinophilic enteropathy with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Eosinophilic enteropathy · United States.

Enrollment
12th of 16
22 · median 28
Started
2023
with 1 other
Phase 2
5 of 26
none open now
Registered
26th of 26
by date
Lead sponsor
1 of 26
Regeneron Pharmaceuticals

Among the 26 studies in Eosinophilic enteropathy with a site in United States, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 26th registered.

Eosinophilic enteropathy

28 studies on the registry are indexed under Eosinophilic enteropathy; 5 are open to participants now.

Browse Eosinophilic enteropathy studies →

Open to participants now

4 of the 26 studies in Eosinophilic enteropathy with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Eosinophilic enteropathy studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Eosinophilic enteropathy with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage.

The aim of the study is to evaluate the effect of dupilumab on relieving EoG (with or without EoD) symptoms and reducing inflammation in the stomach and, if applicable, small intestine in adults and adolescents aged 12 years and older after at least 24 weeks (about 6 months) and up to 52 weeks (1 year) of treatment.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Read the detailed description

This study has 2 parts and a 12-week (about 3 months) Follow-up Period for all participants

  • Part A is an open-label treatment period lasting up to 24 weeks (up to 6 months). "Open-label" means that you and the study doctors and the staff staff will know that you are taking the study drug
  • Part C is an open-label extended treatment period lasting up to 28 weeks (about 7 months). "Extended Treatment Period" means that you will take the study drug for an additional 28 weeks after finishing Part A if you are eligible to take part in this part of the study
03

Conditions studied

  • Eosinophilic Gastritis (EoG)
  • Eosinophilic Duodenitis (EoD)
  • Eosinophilic Gastrointestinal Disease (EGID)
  • Eosinophilic Gastroenteritis

Keywords

  • Eosinophilic Gastritis (EoG) with or without Eosinophilic Duodenitis (EoD)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Adolescent participants will only be enrolled at study sites in countries/regions as permitted by local regulatory authorities and ethic committees (ECs)
  2. Documented endoscopic supporting a pathologic diagnosis of Eosinophilic gastritis (EoG) at least 3 months prior to screening
  3. Screening endoscopic biopsies with a demonstration of eosinophilic infiltration for a diagnosis of EoG, as defined in the protocol
  4. Completed at least 11 of 14 days of EoG/EoD-SQ eDiary data entry in the 2 weeks prior to the baseline visit
  5. History (by participant report) of at least 2 episodes of EoG (with or without EoD) symptoms per week in 8 weeks before screening, as defined in the protocol
  6. An average TSS of ≥ 20 calculated using data collected via the EoG/EoD-SQ eDiary per week for the 2 weeks prior to baseline. An average severity score of ≥4 (on a scale of 0-10) per week for the 2 weeks prior to baseline for at least 2 of the 6 symptoms, as defined in the protocol.

Key Exclusion Criteria:

  1. Body weight less than 40 kg at screening
  2. Prior participation in a dupilumab clinical trial, or past or current treatment with dupilumab
  3. Helicobacter pylori infection
  4. Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening
  5. History of achalasia, Crohn's disease, eosinophilic colitis, ulcerative colitis, celiac disease, and prior gastric or duodenal surgery, as defined in the protocol
  6. Other causes of gastric and, if applicable, duodenal eosinophilia or the following conditions: eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) or hyper-eosinophilic syndrome
  7. History of bleeding disorders, esophageal or gastric varices that, in the opinion of the investigator, would put the participant at undue risk for significant complications from an endoscopy procedure
  8. Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 4 weeks prior to the screening visit. Participants on a food-elimination diet must remain on the same diet throughout the study
  9. Planned or anticipated use of any prohibited medications and procedures during the study
  10. Planned or anticipated major surgical procedure during the study
  11. Receiving tube feeding or parenteral nutritional at screening

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Part A: Treatment Period Part C: Extended Treatment Period Eligible participants from Part A will enter Part C

    Drug: Dupilumab

Interventions

  • Administered as described in the protocol

    Also known as: DUPIXENT®, REGN668, SAR231893

06

What researchers measure

Primary outcomes

  1. Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)

    Time frame: Baseline up to 24 Weeks

Secondary outcomes

  1. Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)

    Time frame: Baseline up to 52 Weeks

  2. Proportion of participants achieving a peak gastric eosinophil count of ≤20 eos/hpf

    Time frame: Up to 52 Weeks

  3. Proportion of participants achieving a peak gastric eosinophil count of ≤30 eos/hpf

    Time frame: Up to 52 Weeks

  4. Proportion of participants achieving both a peak gastric eosinophil count of ≤20 eos/hpf and a peak duodenal eosinophil count of ≤30 eos/hpf

    Time frame: Up to 52 Weeks

  5. Proportion of participants achieving a peak duodenal eosinophil count of ≤30 eos/hpf

    Assessed for only those with duodenal involvement

    Time frame: Up to 52 Weeks

  6. Absolute change in the EoG/EoD-SQ Total Symptom Score (TSS)

    EoG/EoD-SQ is a PRO collected daily via an eDiary. Symptoms are assessed using an 11-point numerical rating scale (0 through 10). Higher scores indicate a higher symptom burden. Symptom scores are summed on each day with a maximum daily score of 60. The TSS is calculated by averaging daily sum scores over 7 days, with a maximum TSS of 60.

    Time frame: Baseline up to 52 Weeks

  7. Percent change in the EoG/EoD-SQ TSS

    Time frame: Baseline up to 52 Weeks

  8. Percent change in peak duodenal tissue eosinophil count (eos/hpf)

    Assessed for only those with duodenal involvement

    Time frame: Baseline up to 52 Weeks

  9. Absolute change in EoG scores from the EoG Histology Scoring System (EoGHSS)

    EoGHSS scores evaluate 11 features of gastric tissue. Total score is the sum of features scores divided by the maximum possible score for the biopsy. Total scores range from 0 - 1.

    Time frame: Baseline up to 52 Weeks

  10. Change in frequency of diarrhea episodes

    Assessed for only those with diarrhea at baseline

    Time frame: Baseline up to 52 Weeks

  11. Change in frequency of vomiting episodes

    Assessed for only those with vomiting at baseline

    Time frame: Baseline up to 52 Weeks

  12. Change in the Normalized Enrichment Scores (NES) for the type 2 inflammation transcriptome signature

    Assessed on gastric tissue Normalized Enrichment Score (NES) reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set.

    Time frame: Baseline up to 52 Weeks

  13. Change in the NES for the type 2 inflammation transcriptome signature

    Assessed on duodenal tissue from participants with EoD NES reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set.

    Time frame: Baseline up to 52 Weeks

  14. Change in the NES for the EoG disease (EoG diagnostic panel (EGDP]) transcriptome signature

    Assessed on gastric tissue NES reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set.

    Time frame: Baseline up to 52 Weeks

  15. Proportion of participants who receive rescue medications or procedures

    Time frame: Up to 52 Weeks

  16. Incidence of treatment-emergent adverse events (TEAEs)

    A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 52 Weeks

  17. Incidence of treatment-emergent serious adverse events (SAEs)

    An SAE is any untoward medical occurrence that at any dose: * Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger) * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event

    Time frame: Up to 52 Weeks

  18. Incidence of treatment-emergent adverse events of special interest (AESIs)

    An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it

    Time frame: Up to 52 Weeks

  19. Incidence of TEAEs leading to permanent discontinuation of study treatment

    A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 52 Weeks

  20. Incidence of anti-drug antibody (ADA)

    Immunogenicity will be characterized per drug molecule by ADA status

    Time frame: Up to 52 Weeks

  21. Titer of ADA

    Immunogenicity will be characterized per drug molecule by ADA status

    Time frame: Up to 52 Weeks

  22. Incidence of neutralizing antibody (NAb) to dupilumab

    Immunogenicity will be characterized per drug molecule by NAb status

    Time frame: Up to 52 Weeks

  23. Concentrations of functional dupilumab in serum at each assessment time point

    The concentrations of functional dupilumab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

    Time frame: Baseline up to 64 Weeks

07

Study locations

53 sites
08

References and documents

Publications

  • Sia T, Bacchus L, Tanaka R, Khuda R, Mallik S, Leung J. Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series. Clin Transl Gastroenterol. 2024 Jan 1;15(1):e00646. doi: 10.14309/ctg.0000000000000646. PubMed 37753954 ↗

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Feb 2026, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
Apr 26, 2023
StartActual
May 3, 2023
Primary completionActual
Feb 23, 2026
CompletionEst.
Nov 25, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05831176
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
May 3, 2023
Primary completion
Feb 23, 2026
Completion
Nov 25, 2026 (estimated)
Last update
Jul 1, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion